Comparison of the anticatabolic effects of leucine and Ca-β-hydroxy-β-methylbutyrate in experimental models of cancer cachexia

Nutrition

Volumn 30, Issue 7-8, 2014, Pages 807-813

  Mirza, Kamran A ^a   Pereira, Suzette L ^b   Voss, Anne C ^b   Tisdale, Michael J ^a  

^a ASTON UNIVERSITY   (United Kingdom)

^b ABBOTT LABORATORIES   (United States)

Author keywords

L Leucine; Muscle; Protein degradation; Protein synthesis; hydroxy methylbutyrate, HMB

Indexed keywords

ANGIOTENSIN II; ATROGIN 1; CALCIUM BETA HYDROXY BETA METHYLBUTYRATE; CHYMOTRYPSIN; LEUCINE; LIPOPOLYSACCHARIDE; MUSCLE RING FINGER 1 PROTEIN; NANDROLONE PHENPROPIONATE; PROTEASOME; PROTEIN HYDROLYSATE; TSI; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN; UNCLASSIFIED DRUG; BETA-HYDROXYISOVALERIC ACID; FBXO32 PROTEIN, MOUSE; MUSCLE PROTEIN; PROTEIN SUBUNIT; PROTEOGLYCAN; PROTEOLYSIS-INDUCING PEPTIDE; TRIM63 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE; VALERIC ACID DERIVATIVE;

ADENOCARCINOMA CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CACHEXIA; CATABOLITE REPRESSION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; LOW DRUG DOSE; MALE; MOUSE; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SYNTHESIS; TUMOR GROWTH; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; COMPARATIVE STUDY; COMPLICATION; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; INBRED MOUSE STRAIN; METABOLISM; NEOPLASM; PROTEIN SUBUNIT; SKELETAL MUSCLE;

ANGIOTENSIN II; ANIMALS; CACHEXIA; DISEASE MODELS, ANIMAL; LEUCINE; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED STRAINS; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BIOSYNTHESIS; PROTEIN SUBUNITS; PROTEOGLYCANS; PROTEOLYSIS; SKP CULLIN F-BOX PROTEIN LIGASES; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES; VALERATES;

EID: 84903382437     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2013.11.012     Document Type: Article

References (19)

1. Khal J., Hine A.V., Fearon K.C.H., Dejong C.H., Tisdale M.J. Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss. Int J Biochem Cell Biol 2005, 37:2196-2206.
2. Emery P.W., Edwards R.H., Rennie M.J., Souhami R.L., Halliday D. Protein synthesis in muscle measured invivo in cachectic patients with cancer. Br Med J 1984, 289:584-586.
3. Busquets S., Alvarez B., López-Soriano F.J., Argilés J.M. Branched-chain amino acids: a role in skeletal muscle proteolysis in catabolic states?. J Cell Physiol 2002, 19:283-289.
4. Smith H.J., Mukerji P., Tisdale M.J. Attenuation of proteasome-induced proteolysis in skeletal muscle by β-hydroxy-β-methylbutyrate in cancer-induced muscle loss. Cancer Res 2005, 65:277-283.
5. May P.E., Barber A., D'Olimpio J.T., Hourihane A., Abumrad N.N. Reversal of cancer-related wasting using oral supplementation with a combination of β-hydroxy-β-methylbutyrate, arginine and glutamine. Am J Surg 2002, 183:471-479.
6. Eley H.L., Russell S.T., Tisdale M.J. Effect of branched-chain amino acids on muscle atrophy in cancer cachexia. Biochem J 2007, 407:113-120.
7. Eley H.L., Tisdale M.J. Skeletal muscle atrophy: a link between depression of protein synthesis and increase in degradation. J Biol Chem 2007, 282:7087-7097.
8. Eley H.L., Russell S.T., Baxter J.H., Mukerji P., Tisdale M.J. Signaling pathways initiated β-hydroxy-β-methylbutyrate to attenuate the depression of protein synthesis in skeletal muscle in response to cachectic stimuli. Am J Physiol Endocrinol Metab 2007, 293:E923-E931.
9. Eley H.L., Russell S.T., Tisdale M.J. Attenuation of depression of muscle protein synthesis induced by lipopolysaccharide, tumor necrosis factor, and angiotensin II by β-hydroxy-β-methylbutyrate. Am J Physiol Endocrinol Metab 2008, 295:E1409-E1416.
10. Eley H.L., Russell S.T., Tisdale M.J. Mechanism of attenuation of muscle protein degradation induced by lipopolysaccharide, tumor necrosis factor-α and angiotensin II by β-hydroxy-β-methylbutyrate. Am J Physiol Endocrinol Metab 2008, 295:E1417-E1426.
11. Mirza K.A., Wyke S.M., Tisdale M.J. Attenuation of muscle atrophy by an n-terminal peptide of the receptor for proteolysis-inducing factor (PIF). Br J Cancer 2011, 105:83-88.
12. Bibby M.C., Double J.A., Ali S.A., Fearon K.C.H., Brennan R.A., Tisdale M.J. Characterization of a transplantable adenocarcinoma of the mouse colon producing cachexia in recipient animals. J Natl Cancer Inst 1987, 78:539-546.
13. Smith H.J., Wyke S.M., Tisdale M.J. Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in skeletal muscle by β-hydroxy-β-methylbutyrate. Cancer Res 2004, 64:8731-8735.
14. Workman P., Twentyman P., Balkwill F., Balmain A., Chaplin D., Double J., et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCR). Guidelines for the welfare of animals with experimental neoplasia (2nd ed.). Br J Cancer 1998, 77:1-10.
15. Whitehouse A.S., Tisdale M.J. Increased expression of the ubiquitin-proteasome pathway in murine myotubes by proteolysis-inducing factor (PIF) is associated with activation of the transcription factor NF-κB. Br J Cancer 2003, 89:1116-1122.
16. Cai D., Frantz J.D., Tawa N.E., Melendez P.A., Oh B.C., Lidov, et al. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice. Cell 2004, 119:285-298.
17. Sandri M., Sandri C., Gilbert A., Skurk C., Calabria E., Picard A., et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004, 117:399-412.
18. López-Pedrosa J.M., Salto R., Vilchez D., Manzano M., Rueda R., Girón M.D. Inhibition of FOXO transcriptional activity by β-hydroxy-β-methylbutyrate (HMB) prevents glucocorticoid-induced muscle fiber atrophy. Clin Nutr Suppl 2012, 7:6.
19. Smith K.L., Tisdale M.J. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer 1993, 67:680-685.